Identification of new susceptibility genes for type 1 diabetes: An update

Current Immunology Reviews

Volumn 4, Issue 3, 2008, Pages 116-133

  Chistiakov, Dimitry A ^a,b,d   Voronova, Natalia V ^b   Chistiakova, Emma I ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b STATE RESEARCH INSTITUTE OF GENETICS AND SELECTION OF INDUSTRIAL MICROORGANISMS   (Russian Federation)

^c N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^d NONE   (United States)

Author keywords

Genome wide association; Susceptibility; Type 1 diabetes

Indexed keywords

EID: 54749111086     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339508785160705     Document Type: Review

References (169)

1. Pociot F, McDermott MF. Genetics of type 1 diabetes mellitus. Genes Immun 2002; 3: 235-49.
2. Ronningen KS, Keiding N, Green A. EURODIAB ACE Study Group: Europe and diabetes: correlations between the incidence of childhood-onset type. I diabetes in Europe and HLA genotypes. Diabetologia 2001; 44 (Suppl 3): B51-9.
3. Valdes AM, Noble JA, Genin E, Clerget-Darpoux F, Erlich HA, Thomson G. Modeling of HLA class II susceptibility to type 1 diabetes reveals an effect associated with DPB1. Genet Epidemiol 2001; 21:212-3.
4. Melanitou E, Fain P, Eisenbarth GS. Genetics of type 1A (immune mediated) diabetes. J Autoimmun 2003; 21: 93-8.
5. Julier C, Lucassen A, Villedieu P, et al. Multiple DNA variant association analysis: application to the insulin gene region in type I diabetes. Am J Hum Genet 1994: 55: 1247-54.
6. Ueda H, Howson JM, Esposito, L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
7. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-8.
8. Todd JA. Statistical false positive or true disease pathway? Nat Genet 2006; 38: 731-3.
9. The International HapMap Consortium. The international HapMap project. Nature 2003; 426: 789-96.
10. Vella A, Cooper JD, Lowe CE, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76: 773-9.
11. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007; 56: 1174-6.
12. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
13. Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39: 1074-82.
14. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 1990; 2: 330-6.
15. Brand OJ, Heward JM, Franklyn JA, Cooper JD, Todd JA, Gough SCL. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol 2007; 66: 508-12.
16. Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17: 349-66.
17. Lord CJ, Bohlander SK, Hopes EA, et al. Mapping of the diabetes polygene Idd3 on mouse chromosome 3 using novel congenic strains. Mamm Genome 1995; 6: 563-70.
18. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-64.
19. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
20. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
21. Zhernakova A, Alizadeh BZ, Bevova M, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81: 1284-8
22. van Heel DA, Franke L, Hunt KA, et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39: 827-9.
23. Mattuzzi S, Barbi S, Carletto A, Ravagnani V, et al. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol 2007; 34: 997-1004.
24. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005; 5: 688-98.
25. King C, Alic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cell during immune unsufficiency generates autoimmunity. Cell 2004; 117: 265-77.
26. Asano K, Ikegami H, Fujisawa T, et al. The gene for human IL-21 and genetic susceptibility to type 1 diabetes in the Japanese. Ann N Y Acad Sci 2006; 1079: 47-50.
27. Asano K, Ikegami H, Fujisawa T, et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007; 68: 384-91.
28. Denny P, Lord CJ, Hill NJ, et al. Mapping of the IDDM locus Idd3 to a 0.35 cM interval containing the Interleukin-2 gene. Diabetes 1997; 46: 695-700.
29. Lyons PA, Armitage N, Argentina F, et al. Congenic mapping of the type 1 diabetes locus, region of mouse chromosome 3: identification of a candidate, to a 780-kb Idd3 segment of ancestral DNA by haplotype mapping. Genome Res 2000; 10: 446-53.
30. Ikegami H, Fujisawa T, Makino S, Ogihara T. Genetic dissection of type 1 diabetes susceptibility gene, Idd3, by ancestral haplotype congenic mapping. Ann N Y Acad Sci 2002; 958: 325-8.
31. Podolin PL, Wilusz MB, Cubbon RM, et al. Differential glycosylation of interleukin-2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine 2000; 12: 477-82.
32. Wrenshall LE, Platt JL. Regulation of T cell homeostasis by heparan sulfate-bound IL-2. J Immunol 1999; 163: 3793-800.
33. Pearson T, Weiser P, Markees TG, et al. Islet allograft survival induced by costimulation blockade in NOD mice is controlled by allelic variants of Idd3. Diabetes 2004; 53: 1972-8.
34. Hunig T, Schimpl A. The IL-2 deficiency syndrome. A lethal disease caused by abnormal lymphocyte survival. In: Durum SK, Muregge K, eds. Cytokine knockouts. Totowa, New Jersey, USA: Humana Press, 1998:1-19.
35. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK Biochemical mechanisms of IL2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8: 615-23.
36. Yamanouchi J, Rainbow D, Serra P, et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007; 39: 329-37.
37. Teuscher C, Wardell B, Lunceford J, Michael S, Tung K. Aod2, the locus controlling development of atrophy in neonatal thymectomy-induced autoimmune ovarian dysgenesis, colocalizes with I12, Fgfb and Idd3. J Exp Med 1996; 183: 631-7.
38. Encinas J, Wicker LS, Peterson LB, et al. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing I12. Nat Genet 1999; 21: 158-60.
39. Samy E, Parker L, Sharp C, Tung K. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+ CD25+ regulatory T-cells in the regional lymph node. J Exp Med 2005; 202: 771-81.
40. Simpson KJ, Jones AL, Forbes Howie A, Hayes PC. Soluble adhesion molecules and interleukin-2 receptor concentrations in patients with autoimmune chronic hepatitis. Eur J Gastroenterol Hepatol 1995; 7: 455-60.
41. Nielsen OH, Ciardelli T, Wu Z, Langholz E, Kirman I. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease. Am J Gastroenterol 1995; 90: 1301-6.
42. Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum Arch Microbiol Immunol 2001; 60: 183-201.
43. Gartner LA, Pfeifer MC, Albini C, Francis GL. Soluble interleukin 2 receptor levels in children with type I insulin-dependent diabetes mellitus. Ann Clin Lab Sci 1995; 25: 44-51.
44. Netea MG, Nancu N. Increased soluble interleukin-2 receptor concentrations in patients with insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 168-8.
45. Hussain MJ, Maher J, Warnock T, Vats A, Peakman M, Vergani D. Cytokine overproduction in healthy first degree relatives of patients with IDDM. Diabetologia 1998; 41: 343-9.
46. Giordano C, Panto F, Caruso C, et al. Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes, 1989;38:310-5.
47. Giordano C, De Maria R, Todaro M, et al. Study of T-cell activation in type I diabetic patients and pre-type I diabetic subjects by cytometric analysis: antigen expression defect in vitro. J Clin Immunol 1993; 13: 68-78.
48. Kretowski A, Mysliwiec J, Szelachowska M, Brzozowski C, Pietruczuk M, Kinalska I. In vitro secretion of interleukin 2 and expression of IL-2 receptor in peripheral blood lymphocytes in high risk of insulin-dependent diabetes mellitus subjects. Arch Immunol Ther Exp (Warsz) 1999; 47: 45-9.
49. Tree TI, Roep BO, Peakman M. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann N Y Acad Sci 2006; 1079: 9-18.
50. Shevach EM. Certified professionals: CD4+CD25+ suppressor T cells. J Exp Med 2001; 193: F41-6.
51. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential fur the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-40.
52. Randolph DA, Fathman CG. CD4+CD25+ regulatory T cells and their therapeutic potential. Annu Rev Med 2006; 57: 381-402.
53. Clayton DG, Walker NM, Smyth DJ, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005; 37: 1243-6.
54. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006; 38: 617-9.
55. Sutherland A, Davies J, Owen CJ, et al. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. J Clin Endocrinol Metab 2007; 92: 3338-41.
56. Marinou I, Montgomery DS, Dickson MC, et al. The interferon induced with helicase domain 1 A946T polymorphism is not associated with rheumatoid arthritis. Arthritis Res Ther 2007; 9:.R40.
57. Andrejeva J, Childs KS, Young DF, et al. The V proteins of paramyxoviruses bind the inducible RNA helicase, mda-5, and inhibit its activation of-the IFN-beta promoter. Proc Natl Acad Sci USA 2004; 101: 17264-9.
58. Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 2005; 175: 2851-8.
59. Van der Werf N, Kloese FG, Rozing J, Hillebrandt JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 169-183.
60. Jun HS, Yoon JW. The role of viruses in type 1 diabetes: two distinct cellular and molecular pathogenic mechanisms of virus-induced diabetes in animals. Diabetologia 2001; 44: 271-85.
61. Yoon JW, Jun HS. Viruses induce type 1 diabetes in animals. Ann N Y Acad Sci 2006; 1079: 138-46.
62. Guo D, Li M, Zhang Y, et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet 2004; 36: 837-41.
63. Owerbach D, Pina L, Gabbay KH. A 212-kb region on chromosome 6q25 containing the TAB2 gene is associated with susceptibility to. type 1 diabetes. Diabetes 2004; 53: 1890-93.
64. Ikegami H, Fujisawa T, Kawabata Y, Noso S, Ogihara T. Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations. Ann N Y Acad Sci 2006; 1079: 51-9.
65. Noso S, Ikegami H, Fujisawa T, et al. Association of SUMO4, as a candidate gene for IDDM5, with susceptibility to type 1 diabetes in Asian populations. Ann N Y Acad Sci 2006; 1079: 41-6.
66. Wang C-Y, Podolsky R, She J-X. Genetic and functional evidence supporting SUMO4 as a type 1 diabetes susceptibility gene. Ann N Y Acad Sci 2006; 1079: 257-67.
67. Kosoy R, Concannon P. Functional variants in SUMO4, TAB2, and NFkB and the risk of type 1 diabetes. Genes Immun 2005; 6: 231-5.
68. Smyth DJ, Howson JMM, Lowe CE, et al. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Genet 2005, 37. 110-1.
69. Sedimbi SK, Shastry A, Park Y, Rumba I, Sanjeevi CB. Association of SUMO4 M55V polymorphism with autoimmune diabetes in Latvian patients. Ann N Y Acad Sci 2006; 1079: 273-7.
70. Caputo M, Cerrone GE, Mazza C, Cedola N, Targovnik HM, Gustavo DF. No evidence of association of CTLA-4 -318 C/T, 159 C/T, 3′ SIR and SUMO4 163 A/G polymorphism with autoimmune diabetes. Immunol Invest 2006; 36: 259-70.
71. Wang CY, Yang P, She JX. Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes. Nat Gienet 2005; 37: 112-3.
72. Sedimbi SK, Luo XR, Sanjeevi CB, et al. SUMO4 M55V polymorphism affects susceptibility to type 1 diabetes in HLA DR3- and DR4-positive Swedish patients. Genes Immun 2007; 8: 518-521.
73. Kawasaki E, Awata T, Ikegami H, et al. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase (PTPN22) gene: Association between promoter polymorphism and type 1 diabetes in Asian populations. Am J Med Genet 2006; 140: 586-93.
74. Tsurumaru M, Kawasaki E, Ida H, et al. Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population. J Clin Endocrinol Metab 2006; 91: 3138-43.
75. Gibbons LJ, Thomson W, Zeggini E, et al. The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis. Rheumatology 2005; 44; 1390-3.
76. Costas J, Perez-Rampin E, Ferreidos-Vidal I, et al. SUMO4 and MAP3K7IP2 single nucleotide polymorphisms and susceptibility to rheumatoid arthritis. J Rheumatol 2006; 33: 1048-51.
77. Orozco G, Sanchez E, Gonzalez-Gay MA, et al. SLC22A4, RUNXI, and SUMO4 polymorphisms are not associated with rheumatoid arthritis: a case-control study in a Spanish population. J Rheumatol 2006; 33: 1235-9.
78. Orozco G, Sanchez E, Gomez LM, et al. Study of the role of functional variants of SLC22A4, RUNX1, and SUMO4 in systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 791-5.
79. Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem 2004; 279; 27233-8.
80. Ehninger A, Mziaut H, Solimena M. Emerging role of SUMO in pancreatic beta-cells. Horm Metab Res 2007; 39: 658-64.
81. Li M, Guo D, Isales CM, et al. SUMO wrestling with type 1 diabetes. J Mol Med 2005; 83: 504-13.
82. Mabb AM, Miyamoto S. SUMO and NF-kappaB ties. Cell Mol Life Sci 2007; 64: 1979-96.
83. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-33.
84. Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003; 144: 2201-7.
85. Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor damma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am 2006; 35: 561-74.
86. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003; 4: 257-91.
87. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20; 284-287.
88. Eftychi C, Howson JMM, Barratt BJ, et al. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11, and PPARG2 in type 1 diabetes. Diabetes 2004; 53: 870-3.
89. Johansen A, Jensen DP, Bergholdt R, et al. IRS1, KCNJ11, PPARγ2 and HNF-1α: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes? Diabetes Obes Metab 2006; 8: 75-82.
90. Waden J, Thorn LM, Forsblom C, et al. Leisure-time physical activity is associated with the metabolic syndrome in type 1 diabetes. Effect of the PPARγ Pro12Ala polymorphism: the FinnDiane Study. Diabetes Care 2007; 30: 1618-20.
91. Bennett ST, Todd JA. Human type 1 diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996; 30: 343-70.
92. Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab Res Rev 2002; 18: 114-7.
93. Botolin S, Faugere M-C, Malluche H, Orth M, Meyer R, McCabe LR. Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in type I diabetic mice. Endocrinology 2005; 146: 3622-31.
94. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268: 178-82.
95. Jacob S. The PPARgamma2 polymorphism Pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 2000; 32: 413-416.
96. Ek J. Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 2001;44: 1170-6.
97. Ricot M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptorgamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
98. Augstein P, Dunger A, Heinke P, et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun 2003; 304: 378-84.
99. Mein CA, Esposito L, Dunn MG, et al. A search for type 1 diabetes susceptibility genes in famiiies from the United Kingdom. Nat Genet 1998; 19: 297-300.
100. Nishimura M, Obayashi H, Maruya E, et al. Association between type 1 diabetes age-at-onset and intercellular adhesion molecule-1 (ICAM-1) gene polymorphism. Hum Immunol 2000; 61, 507-10.
101. Kristiansen OP, Nolsoe RL, Holst H, et al. The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics 2000; 52: 107-11.
102. Nejentsev S, Laine AP, Simell O, Ilonen J. Intercellular adhesion molecule-1 (ICAM-1) K469E polymorphism: no association with type 1 diabetes among Finns. Tiss Antigens 2000; 55: 568-70.
103. Ma J, Mollsten A, Prazny M, Falhammar H, et al. Genetic influences of the intercellular adhesion molecule 1 (ICAM-1) gene polymorphisms in development of type 1 diabetes and diabetic nephropathy. Diabet Med 2006; 23: 1093-9.
104. Guja C, Todd JA, Welsh A, Marshall S, Ionescu-Tirgoviste C. Increased transmission of intracellular adhesion molecule 1 469E allele in type 1 Romanian diabetic families. Diabetologia 1999; 42(Suppl. 1): 327.
105. Nejentsev S, Guja C, McCormack R, et al. The ARG241 allele of the intercellular adhesion molecule-1 is associated with a reduced risk of type 1 diabetes. Lancet 2003; 362: 1723-4.
106. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-64.
107. Vora DK, Rosenbloom CL, Beaudet AL, Cottingham RW. Polymorphisms and linkage analysis for ICAM-1 and the selectin gene cluster. Genomics 1994; 21: 473-7.
108. Joling P, Boom S, Johnson J, et al. Domain 5 of the intercellular adhesion molecule-1(ICAM-1) is involved in adhesion of B-cells and follicular dendritic cells. Adv Exp Med Biol 1994; 355: 131-5.
109. Molgg M, Schwaeble W, Johnson JP, Dierich MP. Generation of recombinant, carbohydrate-free intercellular adhesion molecule-1 (ICAM-1) and ICAM-1 fragments in Escherichia coli and mapping of epitopes recognized by- anti-ICAM-1 monoclonal antibodies. Immunol Lett 1991; 28: 237-43.
110. Iwao M, Morisaki H, Morisaki T. Single-nucleotide polymorphism 1548G > A (E469K) in human ICAM-1 gene affects mRNA splicing pattern and TPA-induced apoptosis. Biochem Biophys Res Commun 2004; 7: 729-35.
111. Casasnovas JM, Stehle T, Liu JH, Wang JH, Springer TA. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc Natl Acad Sci USA 1998; 95: 4134-9.
112. Yang H, Vora DK, Targan SR, Toyodam H, Beaudet AL, Rotter JI. Intercellular adhesion molecule 1 gene associations with immunologic subset of inflammatory bowel disease. Gastroenterology 1995; 109: 440-8.
113. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 1996; 74: 13-33.
114. Hanninen A, Salmi M, Simell O, Jalkanen S. Endothelial cell-binding properties of lymphocytes infiltrated into human diabetic pancreas. Implications for pathogenesis of IDDM. Diabetes 1993; 42: 1556-42.
115. Hanninen A, Taylor C, Streeter PR, et al. Vascular addressins are induced on islet vessels during insulitis in nonobese diabetic mice and are involved in lymphoid cell binding to islet endothelium. J Clin Invest 1993; 92: 2509-15.
116. Yagi N, Yokono K, Amano K, et al. Expression of intercellular adhesion molecule 1 on pancreatic β-cells accelerates β-cell destruction by cytotoxic T-cells in murine autoimmune diabetes. Diabetes 1995; 44: 744-52.
117. Herold KC, Vezys V, Gage A, Montag AG. Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cell Immunol 1994; 157: 489-500.
118. Martin S, Hibino T, Faust A, Kleeman R, Kolb H. Differential expression of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in autoimmune insulitis of NOD mice and association with both Th1 and Th2-type infiltrates. J Autoimmun 1996; 9: 637-43.
119. Martin S. Soluble adhesion molecules in type 1 diabetes mellitus. Horm Metab Res 1997; 29: 639-42.
120. Parkes M, Barrett JC, Prescott NJ. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39: 830-2.
121. Simoncic PD, McGlade CJ, Tremblay ML. PTP1B and TC-PTP: novel roles in immune-cell signaling. Can J Physiol Pharmacol 2006; 84: 667-75.
122. Lorenzen JA, Dadabay CY, Fischer EH. COOH-terminal sequence motifs target the T cell protein tyrosine phosphatase to the ER and nucleus. J Cell Biol 1995; 131: 631-43.
123. You-Ten KE, Muise ES, Itie A, et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 1997; 186: 683-93.
124. Heinonen KM, Nestal FP, Newell EW, et al. T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease. Blood 2004; 103: 3457-64.
125. + myeloid cells lacking T cell protein tyrosine phosphatase inhibit lymphocyte proliferation by an IFN-gamma- and nitric oxide-dependent mechanism. J Immunol 2003; 171: 726-32.
126. Simoncic PD, Lee-Loy A, Barber DL, Tremblay ML, McGlade CJ. The T cell protein phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr Biol 2002; 12: 446-53.
127. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002; 22: 5662-5668
128. Zhu W, Mustelin T, and David M. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J Biol Chem 2002; 277: 35787-90.
129. Van Vliet C, Bukczynska PE, Puryer MA, et al. Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase gene. Gene 2005; 237: 351-60.
130. Aoki N, Matsuda T. A nuclear protein-tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducerand activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 2002; 16: 58-69.
131. Yamamoto T, Sekine Y, Kashima K, et al. The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. Biochem Biophys Res Commun 2002; 297: 811-7.
132. Cronstein BN. Interleukin-6 - a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007; 65(Suppl.1): S11-5.
133. Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007; 40: 453-61.
134. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996; 4: 573-81.
135. Shibuya K, Shirakawa J, Kameyama T, et al. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med 2003; 198: 1829-39.
136. Shirakawa J, Wang Y, Tahara-Hanaoka S, Honda S, Shibuya K, Shibuya A. LFA-1-dependent lipid raft recruitment of DNAM-1 (CD226) in CD4+ T cell. Int Immunol 2006; 18: 951-57.
137. Shibuya K, Lanier LL, Phillips JH, et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity 1999; 11: 615-23.
138. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26: 221-6.
139. Sherrington PD, Scott JL, Jin B, et al. TliSA (PTA1) activation antigen implicated in T cell differentiation and platelet activation is a member of the regulation of expression. J Biol Chem 1997; 272: 21735-44.
140. Tao D, Shangwu L, Qun W, et al. CD226 expression deficiency causes high sensitivity to apoptosis in NK T cells from patients with systemic lupus erythematosus. J Immunol 2005; 174: 1281-90.
141. Smyth DJ, Howson JMM, Payne F, et al. A nalysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases. BMC Med Genet 2006; 7: 20.
142. Holgate ST, Davies DE, Powell RM, Holloway JW. ADAM33: a newly identified gene in the pathogenesis of asthma. Immunol Allergy Clin North Am 2005; 25: 655-68.
143. Del Mastro RG, Turenne L, Giese H, et al. Mechanistic role of a disease-associated genetic variant within the ADAM33 asthma susceptibility gene. BMC Medl Genet 2007; 8: 46.
144. Lesueur F, Oudot T, Heath S, et al. ADAM33, a new candidate for psoriasis susceptibility. PLos ONE 2007; 2: e906.
145. Lesueur F, Lefevre C, Has C, et al. Confirmation of psoriasis susceptibility loci on chromosome 6p21 and 20p13 in French families. J Invest Dermatol 2007; 127: 1403-9.
146. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002; 418: 426-30.
147. Powell RM, Wicks J, Holloway JW, Holgate ST, Davies DE. The splicing and fate of ADAM33 transcripts in primary human airways fibroblasts. Am J Respir Cell Mol Biol 2004; 31: 13-21.
148. Zou J, Zhang R, Zhu F, Liu J, Madison V, Umland SP. ADAM33 enzyme properties and substrate specificity. Biochemistry 2005; 44: 4247-56.
149. Zou J, Zhu F, Liu J, et al, Catalytic activity of human ADAM33. J Biol Chem 2004; 279: 9818-30.
150. Hakonarson H, Grant SFA, Bradfield JP, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007; 448: 591-4.
151. Cambi A, Figdor CG. Levels of complexity in pathogen recognition by C-type lectins. Curr Opin Immunol 2005; 17: 345-51.
152. Robinson MJ, Sancho D, Slack EC, Leibundgut-Landmann S, Reis e Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol 2006; 7: 1258-65.
153. Kanazawa N. Dendritic cell immunoreceptors: C-type lectin receptors for pattern recognition and signaling on antigen-presenting cells. J Dermatol Sci 2007; 45: 77-86.
154. Gullick WJ. The c-erB3/HER3 receptor in human cancer. Cancer Surv 1996; 27: 339-49.
155. Lee H, Alita RW, Sliwkowski MX, Maihle NJ. A naturally occurring secreted human ErB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res 2001; 61: 4467-73.
156. Carver RS, Mathew PM, Russell WE. Hepatic expression of ErbB3 is repressed by insulin in a pathway sensitive to PI-3 kinase inhibitors. Endocrinology 1997; 38: 5195-201.
157. Soh J, Katsuyama M, Ushijima S, et al. Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: implications for erectile dysfunction. Urology 2007; 70: 1019-23:
158. Britsch S. The neuregulin-I/Erb signaling system in development and disease. Ådv Anat Embriol Cell Biol 2007; 190: 1-65.
159. Halleux P, Schurmans S, Schiffman SN, et al. Calcium-binding protein calcyphosine in dog central astrocytes and ependymal cells and in peripheral neurons. J Chem Neuroanat 1998; 15: 239-50.
160. Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083-91.
161. Booth DR, Arthur AT, Teutsch SM, et al. Gene expression and genotyping studies implicate the interleukin 7 receptor gene in the pathogenesis of primary progressive multiple sclerosis. J Mol Med 2005; 83: 822-30.
162. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-62.
163. Lundmark F, Duveleft K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-13.
164. Kittipatarin C, Khaled A. Interlinking interleukin-7. Cytokine 2007; 39: 75-83.
165. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 1993; 262: 1877-80.
166. Hofmeister R, Khaled AR, Benbernou N, Rajnavolgyi E, Muegge K, Durum, S.K. Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 1999; 10: 41-60.
167. Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000; 96: 2803-07.
168. Hamaha J, Machen J, Wright M, et al. Interleukin-7 is a survival factor for CD4+CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells. Diabetes 2006; 55: 158-170.
169. Yates J, Rovis F, Mitchell P, et al. The maintenance of human CD4+CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 2007; 19: 785-99.